The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

AMAG Pharmaceuticals Announces Issuance of New US Patent for Ferumoxytol

12-Aug-2013 | Source : | Visits : 8086
LEXINGTON, Mass. - AMAG Pharmaceuticals Inc. announced in a press release that the United States Patent and Trademark Office (USPTO) has issued a new US patent to AMAG for ferumoxytol, US Patent No. 8,501,158, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in 2020. This Orange Book listed patent covers the use of 500 mg -600 mg of ferumoxytol for the treatment of patients with iron deficiency anemia.

"We believe that this issued patent complements and expands our intellectual property protection for ferumoxytol, providing further specific claims related to approved dosing and formulation," commented Frank Thomas, chief operating officer of AMAG.

AMAG now has four Orange Book listed patents for ferumoxytol, with patent protection through 2020, without patent term extension. AMAG has applied for a patent term extension for an Orange Book listed ferumoxytol patent, which would lengthen that patent term through June 2023.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard™ Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG is working to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.

For additional company information, please visit


Related Articles